Table 3.
Final drug PSM analysis. Lower and upper limits of the 95% confidence interval for the odds ratio. The final substances significantly associated with mortality.
| Final Drug | ATC Code | Drug p-Value | OR | Lower Limit 95% CI | Upper Limit 95% CI | Power | Interactions p < 0.05 |
|---|---|---|---|---|---|---|---|
| DIGOXIN | C01AA05 | 0.011 | 3.81 | 1.20 | 15.84 | 0.553 | Chronic heart disease |
| FOLIC ACID | B03BB01 | 0.001 | 2.32 | 1.36 | 4.08 | 0.520 | Malnutrition Pregnancy |
| MIRTAZAPINE | N06AX11 | 0.001 | 2.17 | 1.32 | 3.65 | 0.517 | Mental illness |
| LINAGLIPTIN | A10BH05 | 0.025 | 2.12 | 1.05 | 4.52 | 0.519 | Chronic kidney disease |
| ENALAPRIL | C09BA02 | 0.012 | 1.93 | 1.12 | 3.39 | 0.513 | Chronic kidney disease |
| ATORVASTATIN | C10AA05 | 0.002 | 1.52 | 1.16 | 2.01 | 0.505 | Dislipemia |
| ALLOPURINOL | M04AA01 | 0.030 | 1.42 | 1.02 | 1.99 | 0.504 | Solid malignant disease |
| ACETYLSALICYLIC ACID | B01AC06 | 0.038 | 1.31 | 1.01 | 1.71 | 0.502 | Chronic heart disease Diabetes, dislipemia, obesity |
OR: odds ratio; p-value: statistical significance.